Within PREDIMED: Higher Olive Oil Intake Linked to 48% Lower CV Mortality

This prospective dose-response analysis within the PREDIMED trial, published in BMC Medicine, examined whether the cardiovascular benefit observed in the overall trial scaled with actual olive oil intake. Among 7,216 high-cardiovascular-risk Spanish adults, the highest tertile of extra virgin olive oil consumption had 39% lower cardiovascular disease risk, and the highest tertile of total olive oil intake had 48% lower cardiovascular mortality, compared with the lowest tertile -- with each 10 g/day increment in EVOO intake reducing cardiovascular risk by 10%.

Why This Study Matters

PREDIMED randomized participants to receive supplemental EVOO, mixed nuts, or a low-fat control diet -- and reported a 30% reduction in cardiovascular events in the EVOO arm. What PREDIMED did not directly answer was whether higher EVOO intake within the trial corresponded to larger benefits. The randomized comparison was between the EVOO arm and the control arm. The actual amount of olive oil that participants consumed varied person-to-person and over time.

This secondary analysis addressed the dose-response question. The Harvard / PREDIMED-affiliated team led by Marta Guasch-Ferre treated the PREDIMED dataset as a prospective cohort and examined the association between baseline and time-updated olive oil intake -- and especially extra virgin olive oil intake -- and cardiovascular outcomes. According to PubMed, the paper appeared in BMC Medicine on May 13, 2014 (DOI: 10.1186/1741-7015-12-78).

The result was a clean dose-response curve. Each additional 10 grams per day of extra virgin olive oil was associated with a 10% reduction in cardiovascular disease risk and a 7% reduction in cardiovascular mortality. The effect was concentrated in the Mediterranean diet intervention arms, not in the low-fat control arm, suggesting that the olive oil and the Mediterranean dietary pattern operate synergistically.

How It Was Designed

The basics are in the study design bar above: 7,216 PREDIMED participants, median 4.8-year follow-up, observational analysis within an RCT, baseline and yearly-updated dietary measurements.

All participants were drawn from the PREDIMED trial cohort -- Spanish adults aged 55 to 80 with no diagnosed cardiovascular disease but at high cardiovascular risk (type 2 diabetes or at least three of: smoking, hypertension, dyslipidemia, overweight, or family history of premature CHD). The randomized arm assignment (Mediterranean diet with EVOO, Mediterranean diet with nuts, or low-fat control) was used as a stratification variable.

Olive oil intake was measured by validated 137-item food frequency questionnaire at baseline and yearly thereafter. The researchers analyzed both total olive oil intake (extra virgin + common olive oil) and extra virgin olive oil intake specifically. Participants were categorized into tertiles of energy-adjusted intake.

The primary endpoints were composite major cardiovascular disease (defined as stroke, myocardial infarction, or cardiovascular death) and total mortality. Endpoints were adjudicated from medical records and the Spanish National Death Index by a blinded endpoint committee. Cox proportional hazards models and generalized estimating equations adjusted for age, sex, intervention arm, BMI, smoking, physical activity, hypertension, diabetes, dyslipidemia, family history of CHD, alcohol intake, and total energy intake.

Importantly, the team also conducted analyses with yearly-updated rather than baseline-only measurements, which captures dietary changes that occurred during the trial in response to the assigned intervention. This is methodologically important: in a 4.8-year trial, what someone ate at year 1 is often different from what they ate at baseline, and using a single baseline measurement would dilute the exposure variable.

What They Found

Comparing the highest tertile of olive oil intake to the lowest, after multivariable adjustment:

Outcome	Hazard Ratio (95% CI)	Risk Reduction	What It Measures
Total olive oil intake (top tertile)	0.65 (0.47-0.89)	35% lower CVD risk	CV disease events
EVOO intake (top tertile)	0.61 (0.44-0.85)	39% lower CVD risk	CV disease events
Total olive oil (top tertile)	0.52 (0.29-0.93)	48% lower CV mortality	Death from CV causes
Per 10 g/day EVOO	10% lower CVD; 7% lower mortality	Dose-response	Linear continuous exposure

Green indicates a favorable direction vs. lowest-tertile intake. All hazard ratios are statistically significant; 95% confidence intervals exclude 1.0.

The associations between cardiovascular events and EVOO intake were significant in the Mediterranean diet intervention groups but not in the low-fat control group. This is a clinically meaningful pattern: the EVOO benefit appears to require, or at least be amplified by, the surrounding Mediterranean dietary context. Olive oil consumed alongside more vegetables, legumes, fish, and whole grains -- the rest of the Mediterranean pattern -- looks different from olive oil consumed against a low-fat reduced-EVOO backdrop.

Reading the Results

The dose-response signal. A linear 10% reduction in cardiovascular disease per 10 g/day of EVOO is the cleanest statement of dose-response in the PREDIMED dataset. It suggests there is no plateau effect within the range of intake observed in the trial -- more EVOO produced more benefit, up to typical Mediterranean-population levels. That finding is reassuring for the underlying mechanism: if the effect were a fluke or artifact of confounding, you would not expect to see a clean linear dose-response.

The EVOO-specific effect. Total olive oil intake (which includes both extra virgin and common/refined olive oil) showed a 35% reduction in cardiovascular events in the top tertile. Extra virgin olive oil specifically showed a larger 39% reduction. The difference is consistent with the polyphenol mechanism: EVOO carries the full phenolic load (typically 200 to 600 mg/kg of total polyphenols), while refined olive oil retains the monounsaturated fatty acid profile but loses most of the phenolic compounds in processing. The EVOO-specific edge -- about 4 percentage points more risk reduction -- is what you would predict if the polyphenols, not just the MUFA, are doing meaningful work.

The intervention-arm interaction. The dose-response effect was statistically significant in the Mediterranean diet arms but not in the low-fat control arm. The likely explanation is that the EVOO is more effective embedded in a Mediterranean food matrix -- the polyphenols, fiber, and plant compounds from accompanying foods may modulate absorption, oxidation, and metabolism. It is also possible that the low-fat control arm consumed too little olive oil overall to generate the dose-response signal. Either interpretation points in the same direction: olive oil is most cardioprotective as part of a Mediterranean dietary pattern.

What Didn't Change

The analysis found no significant association between olive oil intake and cancer mortality or all-cause mortality. The cardiovascular signal was specific to cardiovascular outcomes -- cardiovascular events and cardiovascular death. This contrasts with the later 2022 Harvard cohort analysis (Guasch-Ferre, JACC) which did find broader mortality effects including a 17% reduction in cancer mortality and a 29% reduction in neurodegenerative mortality in U.S. populations.

The analysis is observational within an RCT, not a randomized comparison of olive oil doses. Participants who consumed more olive oil may have differed in other health-relevant ways. The multivariable model adjusted for age, sex, intervention arm, and the major cardiovascular risk factors, which reduces but does not eliminate the possibility of residual confounding.

Finally, the study was conducted in a Mediterranean population with culturally entrenched olive oil consumption. The dose-response curve may differ in populations where olive oil is added to a fundamentally different dietary pattern.

Broader Context

This 2014 dose-response analysis complements the main PREDIMED trial results, which were originally published in NEJM in 2013 and republished in 2018 after methodological re-analysis (Estruch et al., NEJM 2018). The main trial established the 30% relative risk reduction with a Mediterranean diet supplemented with EVOO; the 2014 BMC Medicine analysis adds the within-trial dose-response detail.

The 2011 European Food Safety Authority opinion (Regulation 432/2012) authorized a health claim for olive oil polyphenols and protection of blood lipids from oxidative damage at 5 mg/day of hydroxytyrosol and derivatives. The dose-response curve in this 2014 paper -- 10% lower cardiovascular risk per 10 g/day of EVOO -- is mechanistically consistent with the polyphenol-driven lipid-oxidation pathway established by EUROLIVE (Covas 2006).

Downstream, the Harvard cohort studies extended the dose-response finding to a U.S. population. The 2020 JACC paper (Guasch-Ferre et al.) reported 14% lower cardiovascular risk in U.S. adults consuming more than 7 g/day of olive oil; the 2022 paper reported 19% lower CV mortality and 29% lower neurodegenerative mortality at the same intake threshold. The 2014 PREDIMED secondary analysis and the 2020 / 2022 Harvard cohort papers together establish a remarkably consistent dose-response signal across two very different populations and study designs.

Related Research

Continue exploring olive oil and polyphenol science:

• PREDIMED Republished: Mediterranean Diet + EVOO Cut Major CV Events by 30%
• PREDIMED: EVOO Reduced Atrial Fibrillation Risk by 38%
• A Polyphenol Signature in Urine Predicts Lower CV Risk in PREDIMED

Source: View the original study on PubMed

Olivea's Dosage

This analysis identified a 10% reduction in cardiovascular disease risk per 10 g/day of extra virgin olive oil -- a linear dose-response across the range of intake observed in PREDIMED. The PREDIMED Mediterranean diet arms consumed approximately 50 mL/day (around 45 g) of EVOO. A single tablespoon of Olivea extra virgin olive oil delivers approximately 14 grams. For a concentrated polyphenol dose, each Olivea capsule delivers over 20 mg of hydroxytyrosol per serving in an EVOO matrix; our most recent third-party certificate of analysis confirmed 23.5 mg per capsule.

We share this research for transparency. This is an independent study -- we did not fund it, design it, or conduct it.

Editorial Information

Research note. This article summarizes third-party research published in a peer-reviewed journal. Olivea did not conduct or fund the study. Findings reflect the cited paper only and do not establish efficacy of Olivea products.

.